

ISSN : 2309-3234

TMSS MEDICAL COLLEGE JOURNAL

Volume 04, No. 01, January 2015



An Official Publication of TMSS Medical College, Bogra



TMSS Medical College Journal

January 2015

An Official Publication
of
TMSS Medical College, Bogra

TMSS Medical College Journal

Vol.3, No. 1, January 2015

An Official Publication of TMSS Medical College, Bogra, Bangladesh

Editorial Board

Chairperson : Prof. Dr. Most. Rebeca Khatoon
Editor-In-Chief : Prof. Dr. Md. Abdus Shukur
Executive Editor : Prof. Dr. Md. Azfarul Habib
Publication Editor : Dr. Md. Abdul Mazid
Finance Editor : Dr. Md. Matiur Rahman

Published by

Dr. Md. Abdul Mazid
on behalf of the TMSS Medical College

Graphic Designer

Md. Sirajul Islam
TMSS, Bogra

Members

Prof. Dr. M. A. Gafur
Prof. Dr. Md. Aynul Huq
Prof. Dr. Md. Shahjahan Ali Sarkar
Prof. Dr. Nur-A-Farhana Islam
Dr. Md. Azizar Rahman
Dr. Md. Sheik Abdul Muktaf
Dr. Md. Kamrul Islam

Printed by

TMSS Printing Press
Bogra, Bangladesh

Review Committee

Prof. Dr. Raghieb Ahsan
Prof. Dr. Md. Anup Rahman Chowdhury
Prof. Dr. Md. Abul Hossain Khan

Advisory Board

Prof. Dr. Hosne-Ara Begum
Prof. Dr. A.K.M Ahsan Habib
Prof. Dr. Syed Mainul Hasan
Prof. Dr. S.A.M. Israrul Bari
Prof. Dr. Md. Rafiqul Islam
Prof. Dr. Latifur Rahman
Prof. Dr. Abdul Gaffar
Prof. Dr. Hafiza Arzuman
Dr. A.K.M. Ahsan Habib
Dr. Md. Mostafa Alam

The TMSS Medical College Journal is a peer reviewed Journal. It is published two times a year, (January and July). It accepts original articles, review articles and case reports. Complimentary copies of the journal are sent to libraries of all medical and other relevant academic institutions in the country and selected institutions abroad.

While every effort is always made by the Editorial Board and the members of the Journal Committee to avoid inaccurate or misleading information appearing in the TMSS Medical College Journal, information within the individual article are the responsibility of its author(s). The TMSS Medical College Journal, its Editorial Board and Journal Committee accept no liability whatsoever for the consequences of any such inaccurate and misleading information, opinion or statement.

Address of Correspondence

Executive Editor, TMSS Medical College Journal
TMSS Medical College, Rangpur Road
Thengamara, Bogra, Bangladesh.
Phone: 051-61830, Fax : 051-61830
e-mail: editortmcjournal@gmail.com
Web: www.tmssmedicalcollege.com

Cirrhosis is not Imperative for The Development of Hepatitis B Related Hepatocellular Carcinoma

Islam ASMS^{1*}, Hossain MK², Siddique AB³, Mahtab MA⁴, Mamun AA⁵, Islam MR⁶, Kamal M⁷, Rahman S⁸

1. Dr. Abu Saleh Md. Sadequ Islam, RP, Department of Medicine, Shaheed Ziaur Rahman Medical College Hospital, Bogra.
2. Dr. Md. Kamal Hossain, Assistant Professor, Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogra.
3. Dr. Abu Bakar Siddique, Assistant Professor, Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogra.
4. Dr. Mamun Al Mahtab, Associate Professor, Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka.
5. Dr. Ayub Al Mamun, Associate Professor, Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka.
6. Dr. Md. Rafiqul Islam, Professor and Head, Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogra.
7. Dr. Mohammad Kamal, Professor and Chairman, Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka.
8. Dr. Salimur Rahman, Professor, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka.

* Corresponding author

Abstract

Background: The etiological agent of HCC is known in more than 90% of cases, in South East Asia, hepatitis B is the most common cause. In Bangladesh, HBsAg positivity in the healthy population is 5.4%. The relative risk (RR) of HCC is 100 in HBV carriers versus non - carriers. In HBV carriers with cirrhosis, the RR is 961 compared to uninfected controls. Cirrhosis is an almost invariable precursor to HCC, except in chronic hepatitis B. **Objectives:** To find out the relationship of cirrhosis with the development of hepatitis B-related hepatocellular carcinoma. **Methods:** This observational study was carried out in the Department of Hepatology, BSMMU from January 2012 to December 2013. The study was approved by the Ethical Institutional Review Board (IRB) of BSMMU, Dhaka. The diagnosis of HCC was confirmed by pathological examination or AFP elevation (400ng/ml) combined imaging (CT/MRI) and diagnosis of cirrhosis was made clinically on the basis history, clinical examination and laboratory investigations including imaging or pathological examination after exclusion of hepatitis C virus infection (Anti HCV+ve) and significant alcohol intake (>20 gm. /day). All patients were HBsAg positive done by ELISA test. **Results:** A total 44 patients were included in this study. Among them, 91% were male (n=40) and 09 % were female (n=4). The mean age was 48.2 (±12.9) years. Maximum (50%) patient's ages were belonged to 35-54 years. Cirrhosis was 79.5% (n=35) and no cirrhosis was found 20.5% (n=9). The difference was statistically significant (P = 0.001) among the two groups. Imaging finding of liver size showed hepatomegaly (74%), normal size (19%) and small liver (7%). **Conclusions:** From our observation we can conclude that cirrhosis is an independent risk factor for hepatitis B virus related HCC and also shows that inactive carriers are still at risk of HCC.

Keywords: Hepatitis B; Hepatocellular carcinoma; Cirrhosis

Introduction

HCC is the sixth most common malignant tumor and the third most common cause of cancer deaths worldwide¹. The etiological agent of HCC is known in more than 90% of cases. In South East Asia, hepatitis B is the most common underlying cause. The highest incidence of HCC is in Asia, accounting for about 76% of all cases worldwide².

HBV infection is a serious global health problem. About 378 million people throughout the world are chronically infected with this

virus³. Approximately 15-40% of CHB patients will develop cirrhosis, liver failure and HCC⁴. Bangladesh is within the intermediate zone of prevalence of HBV infection. HBsAg positivity in healthy population is 5.4%⁵. Beasley *et al.*⁶, in a seminal prospective study, showed the relative risk (RR) of HCC to be about 100 in HBV carriers versus non- carriers. The yearly incidence of HCC in the HBV surface antigen (HBsAg) positive group was 0.5%, increasing to 1% by age 70. In HBV carriers with cirrhosis, the

RR was 961 compared to uninfected controls, with an incidence of HCC of 2.5% per year.

Cirrhosis is an almost invariable precursor to HCC, except in chronic hepatitis B. This has led to the concept that cirrhosis is a preneoplastic lesion or that cirrhosis is a common pathway by which different liver diseases result in HCC. The common factor linking all liver diseases with HCC would be the presence of repeated or persistent low - grade necrosis or cell injury, followed by regeneration, predisposing to an increased possibility of oncogenic mutations developing in actively dividing cells in damaged liver tissue⁷.

Based on this hypothesis, we find out the relationship of cirrhosis and non-cirrhosis with the development of hepatitis B-related hepatocellular carcinoma

Materials and Methods

Study Population

This is a hospital based observational study of 44 HCC patients. Patients with HBsAg positive done by ELISA test and features suggestive of HCC attending at outpatient & inpatient department of Hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2012 to December 2013. Aims and objectives of the study along with its procedure, risks and benefits of this study was explained to the patients and attendants in easily understandable local language (Bangla) and then informed written consent was taken from each participant. Prior to the commencement of the study, the research protocol was approved by the Institutional Review Board (IRB) of BSMMU.

Patients were divided into two groups. Group A (Cirrhosis-related HCC) and Group B (non-Cirrhosis with HCC). The inclusion criteria were:

HCC patients were recruited prospectively. The diagnosis of HCC was confirmed by α -fetoprotein elevation (>400 ng/ml) combined with computed tomography (CT) and/or magnetic resonance imaging (MRI) or Pathological examination (Biopsy/FNAC) [Figure 1] and diagnosis of cirrhosis was made by – History, examination and investigations including imaging or Pathological examination (Biopsy). Exclusion criteria were alcohol abuse (>20 g/day) and infection with HCV (anti-HCV positivity).

Procedure for fine needle aspiration (FNA) from liver space occupying lesions SOL(s)

After taking informed written consent, patients laid with empty bladder. The site was painted with iodine solution and draped. Skin and deeper tissue was infiltrated with local anesthesia (2% xylocaine) at the proposed puncture site using a 23 G needle. Under real-time USG guidance and using 22 G disposable spinal needles the cavity was entered and aspirated material was collected. The prepared glass slides were fixed with 95% ethanol and kept in Kaplan's jar after labeling. Samples were sent for cytopathological examination to the Department of Pathology, BSMMU. Dressings were applied at the needle puncture sites and patients were followed up for next 6 hours.

Statistical Analysis

All data was recorded systematically in a preformed data collection sheet and quantitative data expressed as mean $\pm$ SD. Qualitative data analyzed by chi square test and quantitative data by student's T test or Mann Whitney's U test. Differences in laboratory parameters compared using one-way ANOVA. P value of 0.05 was considered to be statistically significant. All statistical computations were performed by using SPSS version 20 (Statistical Package for Social Science).

Results

Demographic and laboratory characteristics

Table I includes the demographic and laboratory parameters of the subjects in the study within two groups, including gender, age, haemoglobin (Hb), platelet count (PLT), prothombin time (PT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum bilirubin, serum albumin and α -fetoprotein (AFP). The Cirrhosis related group and the other group without Cirrhosis had statistically different laboratory results for PLT, PT, INR, ALT, AST, serum bilirubin, serum albumin and α -fetoprotein ($p < 0.05$).

Table I: Demographic and laboratory parameters of the subjects in the study (n=44)

Groups	Cirrhosis (n=35)	No (n=9)	P value
Demographic parameters			
Gender (M/F)	32/3	8/1	.614 ^{ns}
Age (Y) ($\pm$ SD)	48.2 $\pm$ 12.8	48 $\pm$ 14.1	.206 ^{ns}
Laboratory parameters ($\pm$ SD)			
Hb (g/dl)	11.37 $\pm$ 1.8	11.7 $\pm$ 1.51	.208 ^{ns}
PLT ($10^9/L$)	217.2 $\pm$ 97.6	266.6 $\pm$ 118.1	.039 ^s
PT (sec)	15.37 $\pm$ 2.2	14.18 $\pm$ 2.3	.048 ^s
INR	1.29 $\pm$.19	1.19 $\pm$.18	.045 ^s
ALT (U/l)	81.5 $\pm$ 53.8	53.11 $\pm$ 33.7	.038 ^s
AST (U/l)	174.9 $\pm$ 166.9	37.5 $\pm$ 23.9	.012 ^s
T-Bil (mol/l)	112.57 $\pm$ 122.98	26.56 $\pm$ 16.37	.041 ^s
ALB (g/dl)	2.9 $\pm$ 0.6	3.5 $\pm$ 0.4	.003 ^s
AFP (ng/ml)	17241.63 $\pm$ 18479	7469.5 $\pm$ 14186	.049 ^s

ns= not significant, s= significant

Distribution of the study population by age range

Table II shows distribution of the study population by age range. Maximum (50%) patients' ages were belonged to 35-55 years. The mean age was found 48.20 ± 12.92 years with range from 18 to 80 years. The mean age difference was not statistically significant ($P=0.206$) between two groups.

Table II : Distribution of the study population by age range (n = 44)

Age range	Frequency	Percent	Cumulative Percent
< 20	01	02.3	02.3
21 -30	05	11.4	13.7
31- 40	11	25.0	38.7
41- 50	11	25.0	63.7
51- 60	10	22.7	86.4
> 60	06	13.6	100.0
Total	44	100.0	100.0

Gender distribution of the study population

Figure 2 shows male gender was predominant 91% (40) of the study population. Male female ratio was 10:01. Male was also predominant in both groups, which were 91% (32) in cirrhosis - related HCC group and 89% (08) in non-cirrhosis with HCC group. The difference was not statistically significant ($P=0.614$) between the two groups.

Distribution of the study population according to cirrhosis status

Figure 3 shows the cirrhosis status in the study population. Cirrhosis was 79.5% (35) and no cirrhosis was found 20.5% (9). Among cirrhosis group, Child -Pugh A, B and C was 6.8% (3), 31.8% (14) and 40.9% (18) respectively. The difference was statistically significant ($P=0.001$) among the two groups.

Distribution of tumor nodule in the study population

Table III shows tumor nodule in the study population by imaging methods (USG and CT/MRI). Among 44 patients 19(43%) was multiple nodules, 18(41%) was single nodule and 7(16%) was diffuse HCC. Multiple nodules 51.4% (18) was predominant among the cirrhosis group whereas single nodules 88.9% (08) was predominant among the non-cirrhosis group. The

Table III: Distribution of tumor nodule in the study population (n = 44).

Nodule status	Groups				P value* 0.004s
	Cirrhosis		Non-cirrhosis		
	(n = 35)		(n=09)		
n	%	n	%		
Single	10	28.6	8	88.9	
ultiple	18	51.4	1	11.1	
Diffuse	07	20.9	0	0	
Total	35	100	9	100	

s=significant

*Chi square test was done to measure the level of significant difference was statistically significant (P=0.004) among the two groups.

Distribution of liver size by ultrasonography (USG) in the study population

Figure 4 shows distribution of liver size by USG in the study population. Among 44 patients, hepatomegaly, normal size liver and small size liver was 74% (33), 19% (8) and 7% (3) respectively.




Figure 1. Cytopathic feature of Hepatocellular carcinoma (Haematoxylin and eosin stain, Courtesy: Department of Pathology, Bangabandhu Sheikh Mujib Medical University). ID no:18




Figure 2. Gender distribution of the study population (n= 44).




Figure 3: Distribution of the study patients according to cirrhosis status (n=44)




Figure 4. Distribution of Liver size by imaging (n=44)

Discussion

This is the first study from Bangladesh in which the characteristics of HBV related HCC have been studied. HBV infection accounts for most primary HCC and treating HBV infection substantially reduces the risk of HCC development. Chronic HBV infection is recognized as the most important causal factor for HCC in humans.

The incidence of HCC increases with age. The development of HCC is uncommon before 40 years of age in western world. However, the pattern of HCC incidence by age is sometimes dependent on the geographic pattern or on etiologic factors⁸. The age distribution of patients with HCC in the present study was similar to other studies in past. Studies from Bangladesh (M Khan *et al* & Gani ABMS *et al*), India (Sarma MP *et al*), China (Shan R *et al*) and Pakistan (Abbas Z *et al*) have shown the maximum incidence of HCC in the fifth to sixth decade⁹⁻¹³. The male preponderance is similar to our previous Bangladeshi study and other studies from India, Pakistan and France^{9-11,13,14}. The population-based data show a male to female ratio of 3:1–2:1.1.22 However, high preponderance of HCC in males reported in hospital-based data could suggest a gender bias in seeking medical treatment.

Underlying cirrhosis was observed in almost 79.5% of our cases. HCC is accompanied by liver cirrhosis in 70–90%¹⁵. The cirrhosis along with HCC is reported in 70–86% of Indian autopsy studies. The clinical studies have shown 30–80% incidence of associated cirrhosis in HCC¹⁵⁻¹⁶. The present study is in conformity with the previous studies from Bangladesh¹⁰ and India¹¹. The strong association between cirrhosis and HCC is supported by the evidence of its intermediating

role in the pathogenesis of HCC because of chronic viral hepatitis²⁰. The number of patients without cirrhosis (20.5%) in the present study is similar to those in Indian clinical and autopsy studies^{11, 18, 21} and in a study of Kumar *et al*.²². An increased risk was observed for HBV marker irrespective of the cirrhosis status of the HCC patients. This result confirms that HBV is the major etiological factor associated with HCC development. These findings are in agreement with biological data. HBV plays a direct role in liver cell transformation; thus, it can lead to HCC without the development of cirrhosis²³. Like previous studies most of the lesions were multiple in cirrhotic group and single in non-cirrhotic group. However, three fourth of the patients had hepatomegaly, one-fourth having normal size and small size liver.

From our observation we can conclude that cirrhosis is an independent risk factor for hepatitis B virus related HCC and also shows that inactive carriers are still at risk of HCC. Limitation of this study is its small sample size and single center.

Conclusion

HBV is the major risk factors for HCC in Bangladesh and significant risk increase was evident in the absence of cirrhosis. Hepatocellular carcinoma in the early 21st century can be considered a potentially curable disease. Early detection of HCC leads to treatment responses are more durable and cure is more frequently possible. Surveillance is effective for enhancing survival. Therefore surveillance for HCC should be standard care for all patients with cirrhosis and also in hepatitis B patients without cirrhosis.

Conflict of Interest Statement

No potential conflicts of interest are disclosed.

References

1. Jemal A, Bray F, Center MM, Ferly J, Ward E & Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61:69-90.
2. Bosch FX, Ribes J, Cléries R & Diaz M. Epidemiology of hepatocellular carcinoma. *Clin. Liver Dis.* 2005; 9(2): 191 - 211.
3. Franco E, Bagnato B, Maria MG, Meleleo C, Serino L & Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. *World journal Hepatology.* 2012; 4(3):74-80.
4. Hoofnagle JH, Doo E, Liang TJ, Fleischer R & Lok AS. Management of hepatitis B: Summary of a Clinical Research Workshop. *HEPATOLOGY.* 2007; 45(4):1056-1075.
5. Mahtab MA, Rahman S, Foster G, Khan M, Karim MF, Solaiman S, Afroz S. Epidemiology of Hepatitis B Virus in Bangladeshi General Population. *Hepato Bil Pancreat Dis Int* 2008; 7(6), 595-600.
6. Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. *Lancet* 1981; 2: 1129 - 1133.
7. Rudnick DA, Perlmutter DH. Alpha - 1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. *Hepatology* 2005; 42: 514 - 521.
8. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. *Liver Cancer*. New York, Churchill Livingstone, 1997:13-27.
9. M Khan, SA Haq, N Ahmed & MA Matin. Etiology and Clinical Profile of Hepatocellular Carcinoma in Bangladesh. *Bangladesh Med. Res. Counc. Bull.* 1997; 23(1): 16-24.
10. Gani ABMS, Al-Mahtab M, Rahman S, Akbar SMF. Characteristics Features of Hepatocellular Carcinoma in Bangladesh and their Public Health Implications. *Euroasian J Hepato-Gastroenterol* 2013; 3(1):28-30
11. Sarma MP, Asim M, Medhi S, Bharathi T, Diwan R, and Kar P 2012. Viral Genotypes and Associated Risk Factors of Hepatocellular Carcinoma in India. *Cancer Biol Med* ; 9 (3): 172-181
12. Shan R, Junfeng L, Xiaofei D, Yanxiang H, Lina M, Honglei H, Xinyue C, Lai W, et al. 2012. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. *Cancer Immunol Immunother* 61:1433-1439
13. Abbas Z, Siddiqui AU, Luck NH, Hassan M, Mirza R, Naqvi A, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. *J. Pak. Med. Assoc.* 2008; 58(11):602-7
14. Bralet M, Regimbeau J, Pineau P, Dubois S, Loas G, Degos O, Valla D, Belghiti J, Degott C, and Terris B 2000. Hepatocellular Carcinoma Occurring in Non?brotic Liver: Epidemiologic and Histopathologic Analysis of 80 French Cases. *Hepatology* 32:200-204
15. Okuda K, Nakashima T, Sakamoto K, Ikari T, Hidaka H, Kubo Y, et al. Hepatocellular carcinoma arising in non-cirrhotic and highly cirrhotic livers; a comparative study of histopathology and frequency of hepatitis B markers. *Cancer* 1982; 49:450-5.
16. Prabhakar V, Rao KS, Reddy DJ. Primary carcinoma of liver in Vishakhapatnam. *Ind J pathol Microbiol* 1966; 9:54-60.

17. Patil S, Bhuyan BK, Nanda BK. A study of ninety three cases of primary carcinoma of liver. *Ind J Pathol Microbiol* 1982;25:135-8.
18. Sundaram C, Reddy CRRM, Venkataramana G, Benerjea S, Venkatratnam G, Swarnakumari G, et al. Hepatitis B surface antigen, hepatocellular carcinoma and cirrhosis in South India-an autopsy study. *Indian J Pathol Microbiol* 1990;33:334-8.
19. Kumar A, Sreenivas DV, Nagarjuna YR. Hepatocellular carcinoma. The Indian scenario. *Ind J Gastroenterol* 1995; 14:A95.
20. Sung JL. Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. *J Gastroenterol Hepatol* 1997; 12:S370-76.
21. Sarin SK, Thakur V, Guptan RC, et al. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. *J Gastroenterol Hepatol* 2001; 16: 666-673.
22. Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a casecontrol study of 213 hepatocellular carcinoma patients from India. *J Gastroenterol Hepatol* 2007; 22: 1104-1111.
23. Idilman R, De Maria N, Colantoni A, et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. *J Viral Hepat* 1998; 5: 285-299.